Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
Novocure Ltd (NVCR) is up more than +11% after the US FDA approved the company’s Optune Lua to treat metastatic non-small cell lung cancer in adults who have progressed on or after a platinum-based ...
Investor's Business Daily on MSN1d
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
US stock futures traded in a stable manner Wednesday, steadying after the previous season’s tech-inspired losses as quarterly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback